Business Context and Reporting Period
This Form 8-K is a current report filed by Hemispherx Biopharma, Inc. (trading symbol: HEB) on July 17, 2019. The filing details the termination of a prior equity distribution agreement and the execution of a new agreement to facilitate the sale of common stock.
Key Financial Metrics and Capital Structure
The filing does not report revenue, profit, cash flow, margins, or debt levels. The primary financial metric disclosed relates to a potential capital raise:
- Proposed Offering Size: Up to $70 million in aggregate offering price.
- Initial Sales Limit: Sales are capped at $4,508,244 until a new prospectus supplement is filed.
- Transaction Fee: 3.0% of the gross sales price payable to the agent, Maxim Group LLC.
- Use of Proceeds: Working capital and general corporate purposes.
Material Changes
The Company terminated its previous Equity Distribution Agreement with Maxim Group LLC, dated July 23, 2012, as no additional shares could be sold under that agreement (last sale date: February 1, 2019). Subsequently, on July 19, 2019, the Company entered into a new Equity Distribution Agreement with Maxim to sell shares via an "at-the-market" offering.
Outlook, Risks, and Management Commentary
Management intends to use the net proceeds for working capital. The offering is subject to termination by either party with 15 days' written notice. The filing includes standard forward-looking statement disclaimers, noting that the offering may not occur as expected or at all if closing conditions are not met. Investors are cautioned not to rely on representations in the agreement as characterizations of the Company's actual condition.
Investor Verification Checklist
- Verify the current share price and volume to assess the dilution impact of a potential $70 million offering.
- Confirm the Company's current cash position and burn rate to determine the urgency of the capital raise.
- Review the filed Prospectus Supplement (under Form S-3 File No. 333-226059) for specific terms and conditions.
- Monitor future filings to see if the Company files an amended prospectus to lift the initial $4.5 million sales cap.